Capital Fund Management S.A. Glaukos Corp Transaction History

Capital Fund Management S.A.

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 12, 2022	SELL	$34.86 - $63.77 $697 - $1,275	-20 Reduced 0.18%	11,026 $500,000
Q1 2022 May 12, 2022	SELL	$44.33 - $57.82 $461,918 - $602,484	-10,420 Reduced 48.54%	11,046 $638,000
Q4 2021 Feb 10, 2022	BUY	$40.27 - $56.99 $864,435 - $1.22 Million	21,466 New	21,466 $953,000
Q1 2021 May 14, 2021	SELL	$70.43 - $97.42 $1.01 Million - $1.4 Million	-14,368 Closed	0 $0
Q4 2020 Feb 12, 2021	BUY	$48.9 - $75.26 $702,595 - $1.08 Million	14,368 New	14,368 $1.08 Million
Q2 2020 Aug 13, 2020	SELL	$28.78 - $46.83 $562,303 - $914,964	-19,538 Closed	0 $0
Q1 2020 May 13, 2020	SELL	$25.53 - $70.14 $216,034 - $593,524	-8,462 Reduced 30.22%	19,538 $602,000
Q4 2019 Feb 13, 2020	BUY	$54.18 - $65.64 $1.52 Million - $1.84 Million	28,000 New	28,000 $1.53 Million
Q1 2018 May 15, 2018	SELL	$26.05 - $34.5 $601,755 - $796,950	-23,100 Closed	0 $0
Q4 2017 Feb 09, 2018	BUY	$24.5 - $36.01 $565,950 - $831,831	23,100	23,100 $593,000

345

46.7M

132K

188K

Ticker GKOS
Exchange NYSE
Sector Healthcare
Industry Medical Devices
Shares Outstandng 47,596,900
Market Cap $7.63B
Description
Glaukos Corporation, an ophthalmic medical technology and pharmaceutical company, focuses on the development of novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. It offers iStent, iStent inject, iStent inject W micro-bypass stents that enhance aqueous humor outflow inserted in cataract surgery to treat mild-...

Get notified when there are updates to the investment portfolio of Capital Fund Management S.A., based on Form 13F filings with the SEC.

Stay updated on Capital Fund Management S.A. with notifications on news.